title: Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
abstract: BACKGROUND
  FOLFOX (oxaliplatin/leucovorin/5-fluorouracil) and FOLFIRI (irinotecan/leucovorin/5-fluorouracil) are important regimens for the treatment of advanced-stage colorectal cancer (CRC). However, both are associated with severe diarrhea, leading to hospitalization, dose reductions/delays, and even death. In this study, the development of a prediction model for severe diarrhea is described.
  
  
  METHODS
  The records of 200 patients with CRC who had received FOLFOX or FOLFIRI in 3 Canadian cancer centers were reviewed. Clinical and biochemistry parameters potentially associated with diarrhea were abstracted. Logistic regression analysis was applied to develop the final risk model. A risk scoring system, ranging from 0 to 15, was then created from the regression parameters. A receiver operative characteristic curve analysis was done to measure the accuracy of the scoring system.
  
  
  RESULTS
  Important predictors for severe diarrhea included existing comorbidity, patient performance status, an increased baseline bilirubin level, resection of the primary tumor, FOLFOX chemotherapy, metastatic or advanced locoregional versus resected stage IV disease, and the initiation of treatment in the summer months. The receiver operative characteristic analysis had an area under the curve of 0.80 (95% confidence interval, 0.74-0.87). An overall risk score of > or = 7 for a given patient was identified as being the optimal cutoff to maximize the sensitivity (61.4%) and specificity (89.6%) of the prediction tool.
  
  
  CONCLUSIONS
  We developed a prediction tool for severe diarrhea in patients with CRC receiving FOLFOX or FOLFIRI chemotherapy. To make the model available for easy use and access, we have incorporated it on to our risk prediction Web site: www.PredictPatientEvents.com. Prospective external validation is also being planned.
authors.affiliation: British Columbia Cancer Agency, Humber River Regional Cancer Centre, Toronto, Ontario, Canada. gdranit@ca.inter.net
authors.forename: George
authors.initials: G
authors.lastname: Dranitsaris
authors.forename: Amil
authors.initials: A
authors.lastname: Shah
authors.forename: Biljana
authors.initials: B
authors.lastname: Spirovski
authors.forename: Mark
authors.initials: M
authors.lastname: Vincent
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin